4-nitro-2-(4-pyridinyl)-benzoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-nitro-2-(4-pyridinyl)-benzoic acid
• 英文别名: 4-Nitro-2-pyridin-4-ylbenzoic acid
• 化学式: C₁₂H₈N₂O₄
• 分子量: 244.207
• InChiKey: UCIFAGSTUNNOKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  96
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-nitro-2-(4-pyridinyl)-benzoic acid 在 镍 、 sodium cyanoborohydride 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 肼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 25.17h， 生成 N-[4-[N-[2(R)-(tert-butoxycarbonyl)amino-3-(triphenylmethyl)thio]propyl]amino-2-(4-pyridyl)benzoyl]-methionine methyl ester
  参考文献：
  名称：

  Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors

  摘要：

  Cysteine farnesylation at the carboxylate terminal tetrapeptide CAAX of Ras protein is catalyzed by farnesyltransferase. This lipid modification is necessary for regulatory function of both normal and oncogenic Ras. The high frequency of Ras mutation in human cancers has prompted an intensive study on finding ways of controlling oncogenic Ras function. Inhibition of farnesyltransferase is among the most sought after targets for cancer chemotherapy. We report here the design, synthesis and biological characterization of a series of peptidomimetics as farnesyltransferase inhibitors. These compounds are extremely potent towards farnesyltransferase with IC50 values ranging from subnanomolar to low nanomolar concentrations. They have a high selectivity for farnesyltransferase over the closely related geranylgeranyltransferase-I. Structure-activity relationship studies demonstrated that a properly positioned hydrophobic group significantly enhanced inhibition potency, reflecting an improved complementarity to the large hydrophobic pocket in the CAAX binding site. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00252-7
• 作为产物：
  描述：

  2-溴-4-硝基苯甲酸 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium hydroxide 、 copper(l) iodide 、 氯化亚砜 、 lithium chloride 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 18.0h， 生成 4-nitro-2-(4-pyridinyl)-benzoic acid
  参考文献：
  名称：

  Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors

  摘要：

  Cysteine farnesylation at the carboxylate terminal tetrapeptide CAAX of Ras protein is catalyzed by farnesyltransferase. This lipid modification is necessary for regulatory function of both normal and oncogenic Ras. The high frequency of Ras mutation in human cancers has prompted an intensive study on finding ways of controlling oncogenic Ras function. Inhibition of farnesyltransferase is among the most sought after targets for cancer chemotherapy. We report here the design, synthesis and biological characterization of a series of peptidomimetics as farnesyltransferase inhibitors. These compounds are extremely potent towards farnesyltransferase with IC50 values ranging from subnanomolar to low nanomolar concentrations. They have a high selectivity for farnesyltransferase over the closely related geranylgeranyltransferase-I. Structure-activity relationship studies demonstrated that a properly positioned hydrophobic group significantly enhanced inhibition potency, reflecting an improved complementarity to the large hydrophobic pocket in the CAAX binding site. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(99)00252-7

文献信息

• [EN] MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE<br/>[FR] DÉRIVÉS DE MAYTANSINOÏDE, CONJUGUÉS DE CEUX-CI, ET PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2016160615A1

  公开（公告）日：2016-10-06

  Provided herein are maytansinoid derivatives, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.

  本文提供了马替西酚衍生物、其共轭物以及使用它们治疗或预防增生性疾病的方法。
• MAYTANSINOID DERIVATIVES, CONJUGATES THEREOF, AND METHODS OF USE
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：EP3273998A1

  公开（公告）日：2018-01-31
• Maytansinoid Derivatives, Conjugates Thereof, and Methods of Use
  申请人：Regeneron Pharmaceuticals, Inc.

  公开号：US20200385402A1

  公开（公告）日：2020-12-10

  Provided herein are maytansinoid derivatives, conjugates thereof, and methods of treating or preventing proliferative diseases with the same.
• Probing the hydrophobic pocket of farnesyltransferase: aromatic substitution of CAAX peptidomimetics leads to highly potent inhibitors
  作者：Yimin Qian、Juan Jose Marugan、Renae D. Fossum、Andreas Vogt、Said M. Sebti、Andrew D. Hamilton

  DOI：10.1016/s0968-0896(99)00252-7

  日期：1999.12

  Cysteine farnesylation at the carboxylate terminal tetrapeptide CAAX of Ras protein is catalyzed by farnesyltransferase. This lipid modification is necessary for regulatory function of both normal and oncogenic Ras. The high frequency of Ras mutation in human cancers has prompted an intensive study on finding ways of controlling oncogenic Ras function. Inhibition of farnesyltransferase is among the most sought after targets for cancer chemotherapy. We report here the design, synthesis and biological characterization of a series of peptidomimetics as farnesyltransferase inhibitors. These compounds are extremely potent towards farnesyltransferase with IC50 values ranging from subnanomolar to low nanomolar concentrations. They have a high selectivity for farnesyltransferase over the closely related geranylgeranyltransferase-I. Structure-activity relationship studies demonstrated that a properly positioned hydrophobic group significantly enhanced inhibition potency, reflecting an improved complementarity to the large hydrophobic pocket in the CAAX binding site. (C) 1999 Elsevier Science Ltd. All rights reserved.